Skip to main content

Table 2 Association between D-dimer level and clinicopathological characteristics in patients with clinical stage I NSCLC

From: Prognostic significance of preoperative plasma D-dimer level in patients with surgically resected clinical stage I non-small cell lung cancer: a retrospective cohort study

Variables

GroupA:D-dimer, μg/ml ≤1.0

GroupB:D-dimer, μg/ml >1.0

P value

(n = 170)

(n = 67)

n (%)

n (%)

Age at operation, y

  < 70

82 (48.1%)

31 (46.3%)

0.785

  ≥ 70

88 (51.9%)

36 (53.7%)

Gender

 Female

68 (40.0%)

29 (43.3%)

0.643

 Male

102 (60.0%)

38 (56.7%)

Smoking habit

 Never smoker

70 (41.2%)

24 (35.8%)

0.448

 Ever smoker

100 (58.8%)

43 (64.2%)

Serum CEA, ng/ml

  ≤ 5

140 (82.3%)

38 (56.7%)

<0.001

  > 5

30 (17.7%)

29 (43.3%)

Extent of pulmonary resection

 Segmentectomy

24 (14.1%)

10 (14.9%)

0.873

 Lobectomy or more

146 (85.9%)

57 (85.1%)

Tumor location

 Central

16 (9.4%)

8 (12.0%)

0.561

 Non-central

154 (90.6%)

59 (88.0%)

SUVmax of primary tumor

  ≤ 2.3

123 (72.4%)

28 (41.8%)

<0.001

  > 2.3

47 (27.6%)

39 (58.2%)

Tumor size, cm

  ≤ 3

118 (69.4%)

36 (53.7%)

0.023

  > 3

52 (30.6%)

31 (46.3%)

Histological type

 AD

139 (81.7%)

49 (73.1%)

0.140

 Others

31 (28.3%)

18 (26.9%)

Grade

 1

113 (72.4%)

43 (64.2%)

0.738

 2 / 3 / 4

57 (27.6%)

24 (35.8%)

Pleural invasion

 Absent

154 (90.6%)

55 (82.0%)

0.068

 Present

16 (9.4%)

12 (18.0%)

Pathological stage

 Stage I

154 (90.6%)

51 (76.1%)

0.003

 Stage II / III

16 (9.4%)

16 (23.9%)

  1. NSCLC non-small cell lung cancer, CEA carcinoembryonic antigen, AD adenocarcinoma, SUVmax maximum standardized uptake value